Drug intelligence / Profile preview

medroxyprogesterone acetate + atorvastatin

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination of medroxyprogesterone acetate, a progestin hormone, and atorvastatin, a statin medication. Medroxyprogesterone acetate works by balancing estrogen effects in the body, while atorvastatin inhibits HMG-CoA reductase to lower cholesterol. When combined, the metabolism of atorvastatin can be decreased by medroxyprogesterone acetate. This combination has been studied for antischistosomal effects, showing significant impact on Schistosoma worms, with combined treatment being more effective than either drug alone.

Other names: MPA + AtorvastatinMedroxyprogesterone acetate plus Atorvastatin

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PR (Progesterone receptor)

Beyond the preview

Go deeper on medroxyprogesterone acetate + atorvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on medroxyprogesterone acetate + atorvastatin.

Explore the full profile